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The development of congenital heart defects (CHDs) involves a complex interplay between 
genetic variants, epigenetic variants, and environmental exposures. Previous studies have 
suggested that susceptibility to CHDs is associated with maternal genotypes, fetal genotypes, and 
maternal–fetal genotype (MFG) interactions. We conducted a haplotype-based genetic association 
study of obstructive heart defects (OHDs), aiming to detect the genetic effects of 877 SNPs 
involved in the homocysteine, folate, and transsulfuration pathways. Genotypes were available for 
285 mother-offspring pairs with OHD-affected pregnancies and 868 mother-offspring pairs with 
unaffected pregnancies. A penalized logistic regression model was applied with an adaptive least 
absolute shrinkage and selection operator (lasso), which dissects the maternal effect, fetal effect, 
and MFG interaction effects associated with OHDs. By examining the association between 140 
haplotype blocks, we identified 9 blocks that are potentially associated with OHD occurrence. 
Four haplotype blocks, located in genes MGMT, MTHFS, CBS, and DNMT3L, were statistically 
significant using a Bayesian false-discovery probability threshold of 0.8. Two blocks in MGMT 
and MTHFS appear to have significant fetal effects, while the CBS and DNMT3L genes may have 
significant MFG interaction effects.
Introduction
Congenital heart defects (CHDs) are the most prevalent type of birth defect and the leading 
cause of infant mortality attributable to birth defects (Yang et al. 2006). Worldwide, 1.35 
million infants are born with CHDs per year, with an estimated prevalence of 8.1 per 1,000 
live births in North America, and 9.3 per 1,000 live births in Asia (Reller et al. 2008; van der 
Linde et al. 2011). CHDs have many subtypes, and obstructive heart defects (OHDs) are a 
large subgroup of CHDs with obstructive lesions in blood vessels or valves in the right or 
left heart, such as pulmonic stenosis, aortic stenosis, coarctation of the aorta, bicuspid aortic 
valve stenosis, and subaortic stenosis. OHDs account for approximately 25 % of all CHDs, 
and our previous study has shown that OHDs are the most lethal subtype of heart defect in 
infancy (Cleves et al. 2003). Almost 40 % of infants born with serious OHDs die in infancy, 
and many of those who survive may require repeated surgeries and lengthy hospitalizations 
(Cleves et al. 2003; Gilboa et al. 2010; Nembhard et al. 2001). Despite recent medical and 
surgical advances, substantial OHD-attributable morbidity and mortality continues to 
represent a global burden of disease (Botto and Correa 2003).
CHDs are believed to be caused by a complex interplay between environmental exposures, 
genetic, and epigenetic factors. Familial aggregation provides direct evidence for the 
heritability of CHDs (Hobbs et al. 2002), while twin studies have demonstrated that the 
concordance rates of CHD phenotypes are significantly higher among monozygotic twins 
(10.0 %) than dizygotic twins (2.5 %) (Berg et al. 1989). The estimated heritability may vary 
by the phenotypes of cardiovascular malformation; for example, 89 % for bicuspid aortic 
valve and 71–90 % for left ventricular outflow tract malformations (Cripe et al. 2004; 
McBride et al. 2005). In the past few years, we and others have identified multiple genetic 
variants associated with CHDs (Goldmuntz et al. 2008; Hobbs et al. 2006, 2011; Wessels 
and Willems 2010). Though these findings have provided valuable insights into the genetic 
etiology of CHDs, the disease-susceptibility genes identified so far only account for a small 
fraction of CHD prevalence (Fahed et al. 2013). Moreover, relatively few studies have 
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investigated the association between OHDs and genetic variants. The genetic architecture of 
OHDs has remained elusive. It is still unclear how many genetic variants are associated with 
OHDs, how they are distributed in the population, and how they interact with one another to 
cause OHDs.
Investigation of the genetic mechanisms underlying the development of CHDs can be 
especially challenging. CHDs develop during embryogenesis, with multiple maternal–fetal 
metabolic, genomic, and epigenomic interactions. As discussed by Haig, a maternal–fetal 
unit may have three distinct haplotypes at each locus: the maternally derived fetal haplotype 
that is shared by the mother and fetus, the paternally derived fetal haplotype, and the non-
inherited maternal haplotype (Haig 2004). These three types of haplotypes do not always 
have identical effects during pregnancy, and may not always be mutually beneficial to the 
mother and her fetus. Therefore, interaction effects between the mother and her fetus may 
lead to either an opposing or mutually beneficial environment for fetal growth (Sinsheimer 
et al. 2010). Over the past decade, evidence has accumulated demonstrating that maternal–
fetal genotype interactions may be a common mechanism for various complex human 
diseases and birth defects, such as neural tube defects (Relton et al. 2004), schizophrenia 
(Palmer et al. 2002), and autism (Zandi et al. 2006). However, relatively few studies have 
been conducted to detect the MFG interaction with regard to the development of CHDs 
(Lupo et al. 2010).
Here, we report a haplotype-based analysis to dissect the maternal, fetal, and MFG 
interaction effects associated with OHDs in a study population from the National Birth 
Defects Prevention Study (NBDPS; Yoon et al. 2001). The current study included 877 SNPs 
selected from 62 candidate genes. Haplotype blocks were defined by the SNPs in linkage 
disequilibrium (LD). Our method utilized the least absolute shrinkage and selection operator 
(lasso; Tibshirani 1996), a machine learning technique which allows simultaneous effect 
estimation and variable selection, providing an automatic inference for the underlying 
genetic mechanisms. No individual test is required to differentiate maternal, fetal, and MFG 
interaction effects. Finally, we explore possible biological mechanisms with respect to the 
MFG combinations that jointly alter OHD risk.
Materials and methods
Ethics statement
The study was approved by University of Arkansas for Medical Sciences’ Institutional 
Review Board and the National Birth Defects Prevention Study (NBDPS), with protocol 
oversight by the Centers for Disease Control and Prevention (CDC) Center for Birth Defects 
and Developmental Disabilities. All study subjects gave informed written consent. For 
minors, informed written consent was obtained from their legal guardian.
Study population
All subjects were participants of the National Birth Defects Prevention Study, an ongoing 
large-scale case control study covering an annual birth population of 482,000, or 10 % of 
U.S. births. OHD cases were ascertained from birth defect registries in ten participating 
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states that had similar inclusion criteria: Arkansas, California, Georgia, Iowa, 
Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah. A detailed 
description of NBDPS methods can be found elsewhere (Gallagher et al. 2011; Rasmussen 
et al. 2002; Yoon et al. 2001). In the current study, we included all available mother-
offspring pairs with estimated dates of delivery between October 1997 and August 2008. 
Case pairs were defined as those in which the child had at least one type of left or right 
OHDs, including hypoplastic left heart syndrome, tricuspid atresia, pulmonary valve atresia, 
coarctation of the aorta, interrupted aortic arch, aortic stenosis, valvar, pulmonic valve 
stenosis, and ebstein anomaly. Control pairs were defined as those in which the child had no 
structural birth defect. Control families were randomly selected from birth certificate and/or 
birth hospital records (Yoon et al. 2001) and thus represent a random sample from the 
general population. The study population included 294 case pairs and 874 control pairs. A 
comparison of maternal characteristics (Table 1) indicates that there was no significant 
difference between cases and controls with regard to maternal age, race, household income, 
education, smoking, drinking and folic acid exposure (all p values >0.05). However, the 
maternal BMI of case mothers was significantly higher than that of control mothers (p value 
<0.001). In order to adjust for the possible confounding effect of BMI, mother-offspring 
pairs with missing maternal BMI values were excluded from the analysis (9 case pairs and 
26 control pairs), and the final analytical dataset includes 285 case pairs and 868 control 
pairs.
Genotyping and quality control
Our research team commissioned a custom 1,536 SNP panel covering 62 genes in the 
homocysteine, folate, and transsulfuration pathways potentially related to the development 
of CHDs, using the Illumina® GoldenGate custom genotyping platform, as described by 
Chowdhury et al. (2012). We found that the quality of genotype clustering varied 
substantially from SNP to SNP, which we attribute to the in silico design of the custom SNP 
panel without the subsequent quality checks that would be applied to a standard commercial 
array. The initial genotype calls, along with the raw intensity data, were used as inputs to 
SNPMClust, a bivariate Gaussian model-based genotype clustering and calling algorithm 
developed in-house, currently available as an R package on the Comprehensive R Archive 
Network (CRAN; http://cran.r-project.org/). After running SNPMClust, clustering and 
classification plots for all SNPs were visually inspected, leading to dropping a SNP from 
analysis or running SNPMClust under non-default settings in some cases. To ensure high-
quality genotypes, we applied stringent quality control measures and excluded SNPs with 
obviously poor clustering behavior (60 SNPs), no-call rates >10 % (389 SNPs), Mendelian 
error rates >5 % (10 SNPs), minor allele frequencies (MAFs) <5 % (192 SNPs), or 
significant deviation from Hardy–Weinberg Equilibrium in at least one racial group (p < 
10−4, 8 SNPs).
Haplotype blocks
The haplotype blocks were determined using software Haploview version 4.2 (Barrett et al. 
2005). Linkage disequilibrium (LD) was first measured by the D′ statistic between 
neighboring pairs of genetic variants. The Solid Spine of LD criterion, an internally 
developed method by Haploview, was used to determine the haplotype blocks using a 
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threshold of D′ > 0.6. The LD structure was ignored if two SNPs were located more than 
500 kb apart from each other, which is the default setting. A total of 140 haplotype blocks 
were identified for association analysis.
Statistical methods
Recently, we and others proposed using penalized logistic regression methods to dissect the 
maternal, fetal, and MFG interaction effects with mother-offspring pair data (Li et al. 2009, 
2010). In this article, we adapt our method to detect main effects and interaction effects 
between haplotypes, the theoretical details of which can be found elsewhere (Li et al. 2010). 
The proposed method was implemented in R, and the source code is freely available upon 
request. We briefly describe our method below.
Denote H as a risk haplotype that potentially alters the likelihood of disease. The multi-locus 
genotypes within the haplotype block can then be mapped into three possible composite 
diplotypes, namely HH, HH̄ and H̄H̄, where H̄ represents all haplotypes that are different 
from the risk haplotype H. A logistic regression framework is then used to model the 
maternal effect, fetal effect, and MFG interaction effect:
(1)
where
and with xi,f and zi,f defined similarly. This coding strategy follows Cockerham’s orthogonal 
partition method (Cockerham 1954; Kao and Zeng 2002), where am(f) and dm(f) can be 
interpreted as the additive and dominance effects for the risk haplotype at a maternal (fetal) 
block, and iaa, iad, ida, idd can be interpreted as the additive × additive, additive × dominance, 
dominance × additive, and dominance × dominance interaction effects between the maternal 
and fetal blocks, respectively. UW, OW and OB are three dummy variables corresponding 
to three BMI categories: underweight, overweight, and obese.
The maternal–fetal genotype at a haplotype block has seven possible combinations, each 
corresponding to a likelihood of disease (Table 2), and coefficients were estimated by 
maximizing the penalized likelihood with an adaptive lasso penalty (Zou 2006). During 
parameter estimation, phase-ambiguous genotypes were treated as missing data, and phase 
was determined probabilistically via an expectation–maximization (EM) algorithm. The 
initial probability of haplotypes was estimated using the R package haplo. stats, which also 
allows for missing genotypes (Lake et al. 2003; Schaid et al. 2002). In our model, the 
haplotype block may have a large number of multi-locus genotypes. However, the number 
of composite diplotypes is always reduced to three after the haplotype configuration, which 
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significantly lessens data dimensionality. Such a modeling strategy has also been widely 
adopted in previous studies (Lin et al. 2007; Liu et al. 2004, 2011; Zhang et al. 2012). 
Further, adaptive lasso will simultaneously estimate parameters and perform model selection 
through shrinkage. Coefficients that do not significantly differ from 0 are expected to be 
shrunk to 0. Standard errors and confidence intervals of non-zero coefficients are 
empirically estimated using bootstrap resampling (Tibshirani 1996).
It is worthwhile to note that a risk haplotype is defined here for the purpose of dimension 
reduction. A risk haplotype may actually have a protective effect that corresponds to a lower 
likelihood of disease. In the real data application, all haplotypes with a frequency greater 
than 5 % were examined as potential risk haplotypes, and the haplotype with a minimum 
BIC was selected as the optimal risk haplotype. It should be noted that both the adaptive 
lasso estimator and the BIC criteria are asymptotically consistent in terms of model 
selection, which means that the probability of the selected model being the true model 
converges to 1 as the sample size increases (Yang 2005; Zou 2006).
Significance level of an association
The Bayesian false-discovery probability (BFDP) was used to evaluate the significance of 
associations for each haplotype block using the estimated odds ratios (OR) and 
corresponding 95 % confidence intervals (Wakefield 2007). BFDP has become a popular 
strategy to access the noteworthiness of an association by balancing the costs of false 
discovery and non-discovery. In our analyses, we used the most widely accepted practice of 
pre-setting the BFDP threshold at 0.80, (Liu et al. 2010; Oh et al. 2010; Park et al. 2010; 
Spitz et al. 2012; Wakefield 2007; Zienolddiny et al. 2013) which means that missing a true 
association is considered four times more costly than falsely reporting an association. We 
also assume a 5 % prior probability for the existence of an association between OHD 
outcome and haplotype blocks. The upper bound of the 95 % CI of prior OR was assumed to 
be 1.5, meaning that the prior probability of an OR being greater than 1.5 is 2.5 %.
Results
Application of our method to 140 haplotype blocks identified 9 blocks with non-zero 
coefficients, indicating a potential genotype–phenotype association. Information for the 
identified haplotypes is summarized in Table 3. The frequencies of risk haplotypes were 
estimated based on the entire study population, including both cases and controls.
Based on the non-zero coefficients obtained by adaptive lasso estimator, the identified 
blocks fell into three possible categories: maternal main effect (i.e. am, dm ≠ 0), fetal main 
effect (af, df ≠ 0), or MFG interaction effect (i.e. iaa, iad, ida, idd ≠ 0). Among the nine 
identified haplotype blocks, four were found to have a BFDP less than 0.8, and were located 
in the genes MGMT, MTHFS, CBS, and DNMT3L. We further investigated the likelihood of 
disease for each MFG combination, and those 9 blocks exhibit three possible genetic 
mechanisms. In Figs. 1, 2, and 3, we plot one example for each possible mechanism. 
Supplementary materials (Figure S1–S9) provide LD plots and plots of the inferred genetic 
mechanisms for all identified blocks.
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1. Five blocks exhibited only a fetal main effect
The results are summarized in Table 4. A haplotype block within the MGMT gene showed a 
significant association with the disease. This haplotype includes six SNPs covering a 14.5 kb 
region on chromosome 10. The seven MFG combinations at this region correspond to three 
levels of disease likelihood. Two MFG combinations had the lowest likelihood of disease, 
and were used as reference group. We denoted the maternal–fetal genotype combination in 
the reference group as R1 = {HH/HH; HH̄/HH}. Compared to the reference group, the other 
MFG combinations formed two groups with increasing likelihoods of diseases, denoted as 
R2 = {HH/HH̄; HH̄/HH̄; H̄H̄/HH̄} and R3 = {HH̄/H̄H̄; H̄H̄/H̄H̄}. The OR between R1 and 
R2 was estimated to be 1.47 (95 % CI 1.11, 1.96), and the OR between R1 and R3 was 2.16 
(95 % CI 1.22, 3.83). As illustrated in Fig. 1, the fetal haplotype H showed an additive effect 
that decreases the risk of disease, while the risk of disease was unchanged by maternal 
genotypes. Similarly, our results show that the other four blocks may have a dominance 
effect (Figure S2–S5). However, only one block within gene MTHFS had a BFDP less than 
0.8.
2. One block exhibited only a maternal main effect
One block was located within the GSTM4 gene, comprising five SNPs on chromosome 1. 
The result is summarized in Table 4. For this block, the MFG combinations can be 
partitioned into three risk groups, according to the maternal genotypes. We illustrate the 
pattern in Fig. 2. However, this block had a BFDP greater than 0.8.
3. Three blocks exhibited MFG interaction effect
Three blocks were identified with MFG interaction effect (i.e. iaa, iad, ida, idd ≠ 0). These 
three blocks were located within genes DNMT3A, CBS, DNMT3L, respectively, on 
chromosome 2, 21, and 21. The results are summarized in Table 4. The block within gene 
DNMT3L has the smallest size, comprising two highly linked SNPs 0.6 kb apart. Based on 
the estimated coefficients, the MFG combinations were partitioned into three risk groups. As 
illustrated in Fig. 3, when the maternal genotype is HH, the disease risk shows a decreasing 
pattern with the fetal genotypes. However, when the maternal genotype is HH (H̄H̄), the risk 
of disease shows an increasing pattern with the fetal genotype. This pattern of “cross-over” 
was an indication of the potential MFG interaction effect. Similarly, the interactive pattern 
of the blocks in gene CBS and DNMT3A are illustrated in Figure S8–S9. Among the three 
blocks, only CBS and DNMT3L had BFDP values less than 0.8.
Discussion
Our study builds on previous publications that have reported that the genetic susceptibility 
of CHDs may be associated with maternal genotypes, fetal genotypes, and MFG interactions 
(Goldmuntz et al. 2008; Hobbs et al. 2006, 2011; Lupo et al. 2010; Wessels and Willems 
2010). Differentiating those genetic effects from each other, however, remains a challenge in 
maternal and perinatal research. This challenge is partly due to the correlation between 
maternal and fetal genomes. Maternal or fetal effects are likely to confound each other if 
they are tested separately. Therefore, a single model that simultaneously includes both 
maternal and fetal effects is preferred (Shi et al. 2008). In addition, although MFG 
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interactions are thought to exist pervasively in the development of birth defects, genetic 
studies of MFG interactions and our understanding of the complex interactive mechanisms 
are still in their infancy (Sinsheimer et al. 2010). The current study is motivated by the 
importance of and challenges faced by maternal and perinatal research, aiming to (1) dissect 
the genetic effects (i.e. maternal, fetal and MFG interactions) associated with OHDs, and (2) 
investigate the underlying genetic mechanisms for each identified gene (i.e. how a MFG 
combination influences the risk of disease). By employing an innovative logistic regression 
framework with adaptive lasso, we identified four genes potentially associated with OHDs. 
Further analyses of these results suggest that the identified genes may influence the 
phenotype through various genetic mechanisms.
In the current study, we have conducted a haplotype- or region-based association test, which 
is likely to improve the power to detect a causal association by aggregating collective effects 
of small to moderate size, offer an opportunity to capture complex interactions among 
variants, and reduce the burden of multiple testing (Li et al. 2011; Wang et al. 2013). 
However, compared to the conventional single-variant analysis, it is also less convenient to 
assess which particular variants might be driving the associations. In supplementary 
materials (Table S1), we also provide the single-variant analysis results for each SNP within 
the identified haplotype block, using a conventional logistic regression for the corresponding 
genetic effect model inferred by the adaptive lasso estimator. Further extension of the 
haplotype-based approach to a gene-based approach is likely to share the benefit of the 
single-variant approach, and avoid inference of phase-ambiguous haplotypes.
In our results, two haplotypes within gene MGMT and MTHFS exhibited fetal main effects 
only, which are significantly associated with the occurrence of OHDs (BFDP = 0.77 and 
0.68, respectively). MGMT is thought to be involved in the prevention of DNA damage and 
oxidative stress, and previous studies have shown that MGMT gene expression is related to 
antioxidant mechanisms (Niture et al. 2007). Previous work by our research group has also 
found associations between multiple maternal SNPs of MGMT and maternal metabolites, 
such as levels of glutamylcysteine (GluCys) and plasma folate (Chowdhury et al. 2012). In 
particular, the plasma folate levels significantly varied by the maternal genotypes of 
rs10764896 (located in MGMT) in both cases and controls, indicating a potential 
involvement of rs10764896 in folate-related metabolite plasma concentrations. This SNP 
(rs10764896) is within the haplotype block identified in the current study. The MTHFS gene 
encodes a key enzyme involved in the folate pathway that metabolizes 
formyltetrahydrofolate. The folate pathway is interconnected with methionine metabolism 
by providing the methyl groups for the remethylation of homocysteine back to methionine. 
Our previous study also found maternal SNPs within MTHFS that are related to total plasma 
glutathione (GSH) levels (Chowdhury et al. 2012). Though experimental validation is 
needed to elucidate the functional mechanism of SNPs in MGMT and MTHFS, our current 
finding has provided additional evidence for their potential involvement in the development 
of CHDs.
Two haplotypes within the CBS and DNMT3L genes exhibited MFG interaction effects 
which are significantly associated with the occurrence of OHDs (BFDP = 0.46 and 0.49, 
respectively). The CBS gene is located on chromosome 21q22.3, and CBS deficiency is a 
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common cause of an inherited metabolic disorder, classical homocystinuria. The CBS gene 
catalyzes the conversion of homocysteine to cystathionine, the first step in the 
transsulfuration pathway. Studies have found that the expression of fetal CBS is 
concentrated in the neural and cardiac tissues, supporting a hypothesis of its involvement in 
embryo cardiac development (Quere et al. 1999; Robert et al. 2003). In particular, a recent 
study in Han Chinese population identified a functional variant (rs2850144) in CBS that is 
significantly associated with the genetic susceptibility to CHDs (Zhao et al. 2012). This SNP 
(rs2850144, BP: 43370045) was not genotyped in our study, but it is located approximately 
5.5 kb from the identified haplotype block (BP 43354960–43364494). It is very likely that 
rs2850144 is in strong LD with the haplotype block identified in our study, and our results 
also suggest that the maternal CBS gene may interact with fetal CBS to jointly alter genetic 
susceptibility to the disease. The DNMT3L gene encodes an enzyme that stimulates de novo 
methylation by DNA cytosine methyltransferase 3 alpha, which is thought to be required for 
the establishment of maternal genomic imprintings (Hata et al. 2002). This enzyme also 
mediates transcriptional repression through interaction with histone deacetylase 1 (Aapola et 
al. 2002; Deplus et al. 2002). Studies have reported association of DNMT3L with multiple 
conditions, such as ovarian endometriosis (Borghese et al. 2012), embryonal carcinoma 
(Minami et al. 2010), and cervical cancer (Gokul et al. 2007). Further studies will be 
necessary to validate the potential involvement of DNMT3L in the development of CHDs.
A few limitations of our study should be noted. First, although all of the identified 
haplotypes had p values less than the nominal significant threshold of 0.05, none of them 
would remain significant with the stringent Bonferroni correction. However, Bonferroni 
correction is usually overly conservative, and BFDP has been suggested as a good 
alternative, especially in candidate gene-based studies when there is strong priori probability 
that the genes are likely to be associated with the disease. Second, two types of gene–gene 
interactions are possible during pregnancy: intra-generational interaction within either the 
maternal or fetal genome, and inter-generational interaction between maternal and fetal 
genomes. Our current analysis only considers the inter-generational interactions between 
maternal and fetal genes from the same genomic region (LD block). Intra-generational 
interaction and MFG interaction between genes from different regions are not within the 
scope of the current study. Third, the current study only included common SNPs that have 
minor allele frequencies (MAFs) of 5 % or higher. Evidence from Phase III of the 
International HapMap Project and 1,000 Genomes Project have supported that rare variants 
with lower MAFs may contribute considerately to the development of complex human 
diseases (Abecasis et al. 2012; Altshuler et al. 2010). However, our current analysis tests 
each haplotype block, which is less easy to take into account the rare variants. Fourth, the 
focus of our study is to investigate the genetic susceptibility of OHDs. We are able to 
control the potential confounding effect of environmental factors such as BMI, but 
considering potential gene-by-environment interactions would substantially increase the 
model complexity and are not considered in the current study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MGMT (Block 4)—Fetal main effect only. Fetal haplotype H showed an additive effect that 
was protective of the disease, while the risk of disease was unchanged by maternal 
genotypes
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GSTM4 (Block 1)—maternal main effect only. Maternal haplotype H showed an additive 
effect that was protective of the disease, while the risk of disease was unchanged by fetal 
genotypes
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DNMT3L (Block 9)—MFG interaction effect. Maternal and fetal genotypes showed 
interactive pattern in terms of disease risk
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Table 1
Maternal characteristics: NBDPS 1997–2007
Cases (N = 294) Controls (N = 874) p value
Mother’s age at conception [mean (SD)] 28.0 (5.8 %) 27.7 (5.9 %) 0.401
Mother’s BMI at conception [n (%)] <0.001
 Underweight 2 (0.7 %) 35 (4.1 %)
 Normal 126 (44.2 %) 460 (54.3 %)
 Overweight 82 (28.8 %) 195 (23.0 %)
 Obese 75 (26.3 %) 158 (18.6 %)
 Missing 9 26
Mother’s race [n (%)] 0.330
 African American 30 (10.2 %) 88 (10.1 %)
 Caucasian 221 (75.2 %) 618 (70.7 %)
 Hispanic 30 (10.2 %) 124 (14.2 %)
 Others 13 (4.4 %) 44 (5.0 %)
Household income [n (%)] 0.076
 $0–$10,000 38 (13.4 %) 112 (13.6 %)
 $10,000–$30,000 89 (31.4 %) 236 (28.6 %)
 $30,000–$50,000 80 (28.3 %) 190 (23.1 %)
 >$50,000 76 (26.9 %) 286 (34.7 %)
 Missing 11 (3.7 %) 50 (5.7 %)
Mother’s education [n (%)] 0.942
 <12 years 40 (13.6 %) 117 (13.4 %)
 High school degree or equivalent 71 (24.1 %) 208 (23.8 %)
 1–3 years of college 86 (29.3 %) 244 (27.9 %)
 ≥4 years of college or Bachelor degree 97 (33.0 %) 305 (34.9 %)
Smoking [n (%)] 0.459
 Yes 46 (15.6) 153 (17.5 %)
 No 248 (84.4) 720 (82.5 %)
 Missing 0 1
Drinking [n (%)] 0.518
 Yes 59 (20.1 %) 191 (21.9 %)
 No 234 (79.9 %) 680 (78.1 %)
 Missing 1 3
Folic acid exposure [n (%)] 0.572
 Yes 164 (55.8 %) 504 (57.7 %)
 No 130 (44.2 %) 370 (42.3 %)
p value less than 0.05 (in bold) indicates a significant difference between case mothers and control mothers
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Table 2




 HH (1, 1, −1/2, −1/2)a (1, 0, −1/2, 1/2) –b
 HH̄ (0, 1, 1/2, −1/2) (0, 0, 1/2, 1/2) (0, −1, 1/2, −1/2)
 H̄H̄ –b (−1, 0, −1/2, 1/2) (−1, −1, −1/2, −1/2)
a
Coding values for (xi,m, zi,m, xi,f, zi,f). According to Eq. (1), the corresponding log-odds of being a case pair with a normal maternal weight is: 
b
Combination not possible under Mendelian transmission
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